Patecibart

帕特西拜单抗

Report date: 2026/03/19 20:00:18

Base Information

Drug NamePatecibart
Drug Alias NameGetagozumabGMA-301GMA-301-AGMA-301-B
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEndothelin receptor type A antagonists
TargetsEndothelin receptor type A
Therapy Area/IndicationsPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGmax Biopharm Llc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGmax Biopharm Llc
Inactive CompaniesGmax Biopharm Australia Pty Ltd
Active IndicationsPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A